Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Hookipa Biotech
Hookipa Biotech
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Overcoming CMC challenges in cell and gene therapy: part II
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC...
SNIPR Biome receives funding to progress CRISPR medicine SNIPR001 into clinical trials
Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation
Kindeva Drug Delivery appoints Denis Johnson as Chief Operating Officer
Denis will be responsible for optimising global operations for the company
SeaBeLife awarded over €1.5 million in i-Nov innovation competition
Funding for company’s SeaBeEYE project will be used to develop a new therapeutic approach for geographic atrophy, a form of age-related macular degeneration
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Drug Delivery
Hookipa achieves $10 million towards immunotherapy for KRAS-mutated cancers
“We’re excited to advance the HB-700 program, our third in oncology, and we’re eager to explore the potential of our technology in addressing another unmet need in cancer.”
Regulatory
FDA accepts HOOKIPA’s IND application for HB-300 for the treatment of metastatic castration-resistant prostate cancer
Novel arenaviral immunotherapy is directed against the prostate cancer targets PAP and PSA; Phase I/II trial to commence by early 2023
Research & Development
Hookipa and Gilead amend HIV immunotherapy agreement
Under the original agreement, Gilead would assume rights for further development following a joint research phase
Research & Development
Hookipa announces clinical collaboration with Merck USA
The collaboration will evaluate the combination of Hookipa’s arenaviral immunotherapeutic, and Merck’s Keytruda as treatment for patients with advanced head and neck squamous cell carcinoma
Research & Development
Hookipa Gilead collaboration reaches major milestones
The license agreement to focus on HBV and HIV has now delivered 24 research-grade vectors
Recruitment
Dr Jan van de Winkel joins Hookipa as Chairman of its Board of Directors
Reinhard Kandera appointed CFO of Hookipa Biotech
Subscribe now